
    
      Primary Objectives

      1. To determine the feasibility ad safety of anti-CD19/BCMA CAR-T cells in treating patients
      with BCMA-positive multiple myeloma.

      Secondary Objectives

        1. To access the efficacy of anti-CD19/BCMA CAR-T cells in patients with multiple myeloma.

        2. To determine in vivo dynamics and persistency of anti-CD19/BCMA CAR-T cells.
    
  